The Food and Drug Administration has expanded eligibility for the Pfizer BioNTech booster to children aged 12 and older.
The expansion is emergency authorization.
The decision comes after the Omicron variant has become the dominant strain in the Continental United States. The variant is also known to exhibit immune escape among the available vaccines, but data suggest that boosters significantly improve resistance to the emerging variant.
The variant has also caused many school districts in the Continental United States to convert to online models of learning. As of broadcast, there is no recorded case of Omicron on-island and the Guam Department of Education has made statements about returning to online learning.
According to the FDA’s Website, the amended EAU also shortens the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 Vaccine and a booster dose to at least five months.
It also allows for a third primary series dose for certain immunocompromised children 5 through 11 years of age.